3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
6
Fatigue
6
Breast Neoplasms
5
Anxiety Disorders
3
Psychological Well-Being
2
Pain
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Depression
2
Caregiver Burden
2
Uterine Neoplasms
1
Tuberous Sclerosis
1
Substance-Related Disorders
1
Smoking Cessation
1
Sleep Wake Disorders
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neoplasm Regression, Spontaneous
1
Multiple Myeloma
1
Malignant Hepatobiliary Neoplasm
1
Lymphoma
1
Leukemia
1
Hematopoietic Cell Transplantation Recipient
1
Head and Neck Neoplasms
1
Interventions
Ultrasonic Waves
1
Tobacco Use Cessation Devices
1
Therapeutics
1
Nicotine Replacement Therapy
1
Nicotine Chewing Gum
1
Focus Groups
1
Ethanol
1
Educational Status
1
Dosage Forms
1
Cognitive Behavioral Therapy
1
Behavior Therapy
1
Acceptance and Commitment Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Substance-Related Disorders
×
Acceptance and Commitment Therapy
×
Clear all
NCT05643027
2026-05-14
ACTION
Dana-Farber Cancer Institute
Phase NA
Completed
40 enrolled